Lisa Derosa

List of Publications by Year
in descending order

99 papers	9,401 citations	94433 37 h-index	46799 89 g-index
104 all docs	104 docs citations	104 times ranked	13976 citing authors

#	Article	IF	Citations
1	Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nature Medicine, 2022, 28, 315-324.	30.7	225
2	The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. Cancer Discovery, 2022, 12, 958-983.	9.4	10
3	Immune system and intestinal microbiota determine efficacy of androgen depletion therapy against prostate cancer.. Journal of Clinical Oncology, 2022, 40, 168-168.	1.6	0
4	Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nature Medicine, 2022, 28, 535-544.	30.7	158
5	Modulation of cancer immunotherapy by dietary fibers and over-the-counter probiotics. Cell Metabolism, 2022, 34, 350-352.	16.2	7
6	A probiotic supplement boosts response to cancer immunotherapy. Nature Medicine, 2022, 28, 633-634.	30.7	5
7	Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. , 2022, 10, e004191.		23
8	Cancer Induces a Stress Ileopathy Depending on Î²-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis. Cancer Discovery, 2022, 12, 1128-1151.	9.4	44
9	Antibiotic Exposure and Immune Checkpoint Inhibitors in Patients With NSCLC: The Backbone Matters. Journal of Thoracic Oncology, 2022, 17, 739-741.	1.1	4
10	Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinoma. Bulletin Du Cancer, 2022, 109, 2S31-2S38.	1.6	2
11	Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. Clinical Genitourinary Cancer, 2022, 20, 488-494.	1.9	4
12	Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. Clinical Genitourinary Cancer, 2021, 19, 32-40.	1.9	17
13	Physiologic colonic uptake of 18F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1550-1559.	6.4	15
14	Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI Insight, 2021, 6, .	5.0	143
15	Oral administration of Akkermansia muciniphila elevates systemic antiaging and anticancer metabolites. Aging, 2021, 13, 6375-6405.	3.1	75
16	Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death and Disease, 2021, 12, 258.	6.3	113
17	Contourner la rÃ©sistance Ã lâ€™immunothÃ©rapie des cancersÂ: interventions centrÃ©es sur le microbiome intestinal. Bulletin De L'Academie Nationale De Medecine, 2021, 205, 364-382.	0.0	0
18	Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. Cell Death and Differentiation, 2021, 28, 2778-2796.	11.2	72

#	Article	IF	Citations
19	Fecal microbiota transplantation: can it circumvent resistance to PD-1 blockade in melanoma?. Signal Transduction and Targeted Therapy, 2021, 6, 178.	17.1	3
20	Multifaceted modes of action of the anticancer probiotic Enterococcus hirae. Cell Death and Differentiation, 2021, 28, 2276-2295.	11.2	18
21	Intestinal Akkermansia muciniphila predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study.. Journal of Clinical Oncology, 2021, 39, 9019-9019.	1.6	5
22	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nature Medicine, 2021, 27, 1432-1441.	30.7	216
23	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. Cell Death and Differentiation, 2021, 28, 3297-3315.	11.2	31
24	Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?. Cancer Discovery, 2021, 11, 2396-2412.	9.4	81
25	Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. Immunity, 2021, 54, 1883-1900.e5.	14.3	233
26	Circulating acetylated polyamines correlate with Covid-19 severity in cancer patients. Aging, 2021, 13, 20860-20885.	3.1	9
27	Immunodynamics of explanted human tumors for immunoâ€›oncology. EMBO Molecular Medicine, 2021, 13, e12850.	6.9	9
28	Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. ESMO Open, 2021, 6, 100312.	4.5	17
29	On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective Study. Clinical Genitourinary Cancer, 2020, 18, e145-e156.	1.9	4
30	The immuno-oncological challenge of COVID-19. Nature Cancer, 2020, 1, 946-964.	13.2	96
31	The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Nonâ€“Small Cell Lung Cancer. Cancer Immunology Research, 2020, 8, 1243-1250.	3.4	154
32	Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. Cell, 2020, 182, 1401-1418.e18.	28.9	663
33	Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors. OncoImmunology, 2020, 9, 1794423.	4.6	7
34	Immune responses during COVID-19 infection. OncoImmunology, 2020, 9, 1807836.	4.6	103
35	Antibiotics impair immunotherapy for urothelial cancer. Nature Reviews Urology, 2020, 17, 605-606.	3.8	4
36	Cross-reactivity between tumor MHC class Iâ€“restricted antigens and an enterococcal bacteriophage. Science, 2020, 369, 936-942.	12.6	217

#	Article	IF	Citations
37	COVID-19: a challenge for oncology services. OncoImmunology, 2020, 9, 1760686.	4.6	7
38	New pathways in immune stimulation: targeting OX40. ESMO Open, 2020, 5, e000573.	4.5	56
39	Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. European Urology, 2020, 78, 195-206.	1.9	192
40	Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy. OncoImmunology, 2020, 9, 1774298.	4.6	22
41	Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses. OncoImmunology, 2020, 9, 1789284.	4.6	4
42	Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer. OncoImmunology, 2020, 9, 1677427.	4.6	8
43	Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. Nature Medicine, 2020, 26, 919-931.	30.7	118
44	Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.. Journal of Clinical Oncology, 2020, 38, 3095-3095.	1.6	17
45	Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma. Oncotarget, 2020, 11, 4582-4592.	1.8	14
46	The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?. Annals of Oncology, 2019, 30, 1572-1579.	1.2	153
47	A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation. Angiogenesis, 2019, 22, 383-395.	7.2	5
48	Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre. European Journal of Cancer, 2019, 107, 79-85.	2.8	56
49	The intimate relationship between gut microbiota and cancer immunotherapy. Gut Microbes, 2019, 10, 424-428.	9.8	98
50	Renal Cell Carcinoma with bone metastases isnâ€™t always bad. Oncotarget, 2019, 10, 4511-4512.	1.8	2
51	The impact of the intestinal microbiota in therapeutic responses against cancer. Comptes Rendus - Biologies, 2018, 341, 284-289.	0.2	65
52	Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors. Clinical Genitourinary Cancer, 2018, 16, e663-e667.	1.9	12
53	PD-1 Blockade in Renal Cell Carcinoma. , 2018, , 345-355.		0
54	Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Annals of Oncology, 2018, 29, 1437-1444.	1.2	615

#	Article	IF	Citations
55	The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1. OncoImmunology, 2018, 7, e1434468.	4.6	51
56	Gut microbiome influences efficacy of PD-1â€“based immunotherapy against epithelial tumors. Science, 2018, 359, 91-97.	12.6	3,689
57	Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680â€“7. European Urology, 2018, 73, e11-e12.	1.9	0
58	Activity of third line (3L) therapy in patients with metastatic non-clear-cell renal cell carcinoma (mnccRCC).. Journal of Clinical Oncology, 2018, 36, 650-650.	1.6	0
59	Efficacy of treatment beyond third-line (3L) in metastatic clear-cell renal cell carcinoma (mccRCC).. Journal of Clinical Oncology, 2018, 36, 647-647.	1.6	0
60	Anticorps monoclonaux en oncologie : dÃ©clencher une rÃ©ponse immunitaire en plus de la rÃ©duction tumorale spÃ©cifique.. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 707-735.	0.0	0
61	The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treatment Reviews, 2017, 55, 71-82.	7.7	56
62	Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel GroupÂstudy. European Journal of Cancer, 2017, 80, 55-62.	2.8	18
63	Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. Oncology, 2017, 92, 269-275.	1.9	5
64	Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy. Clinical Genitourinary Cancer, 2017, 15, e1081-e1088.	1.9	6
65	The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. European Urology, 2017, 71, 680-687.	1.9	213
66	Targeting the Pd-1 Pathway in Renal Cell Carcinoma: A Review. Journal of Onco-Nephrology, 2017, 1, 179-187.	0.6	1
67	Antibiotics prescription to decrease progression-free survival (PFS) and overall survival (OS) in patients with advanced cancers treated with PD1/PDL1 immune checkpoint inhibitors.. Journal of Clinical Oncology, 2017, 35, 3015-3015.	1.6	11
68	Inter and intra-tumor heterogeneity of PD-L1 and MET expression in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2017, 35, 4569-4569.	1.6	17
69	Brain metastases (BM) from renal cell carcinoma treated with nivolumab: Evidence of early brain flare?. Journal of Clinical Oncology, 2017, 35, 520-520.	1.6	15
70	Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma. Oncology Reviews, 2016, 10, 298.	1.8	21
71	Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget, 2016, 7, 54564-54571.	1.8	116
72	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. PLoS ONE, 2016, 11, e0151662.	2.5	56

#	Article	IF	Citations
73	Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer. PLoS ONE, 2016, 11, e0158952.	2.5	45
74	Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer. Molecular Diagnosis and Therapy, 2016, 20, 255-263.	3.8	10
75	Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. Investigational New Drugs, 2016, 34, 760-770.	2.6	29
76	Long-Term PSA Control with Repeated Stereotactic Body Radiotherapy in a Patient with Oligometastatic Castration-Resistant Prostate Cancer. Oncology Research and Treatment, 2016, 39, 217-220.	1.2	9
77	[18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results. Radiation Oncology, 2016, 11, 9.	2.7	70
78	Safety of available treatment options for renal cell carcinoma. Expert Opinion on Drug Safety, 2016, 15, 1097-1106.	2.4	11
79	Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 167.e17-167.e23.	1.6	22
80	Prognosis of brain metastasis (BM) in metastatic renal cell carcinoma (mRCC): Experience from Gustave Roussy (IGR).. Journal of Clinical Oncology, 2016, 34, 4561-4561.	1.6	3
81	Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study. Oncotarget, 2016, 7, 40085-40094.	1.8	17
82	A new prognostic model of survival in second-line targeted therapy (TT) for metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2016, 34, e16113-e16113.	1.6	0
83	Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. Prostate, 2015, 75, 1329-1338.	2.3	24
84	Small-Bowel Neuroendocrine Tumor and Retroperitoneal Fibrosis: Efficacy of Octreotide and Tamoxifen. Tumori, 2015, 101, e24-e28.	1.1	5
85	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. Annals of Surgical Oncology, 2015, 22, 2094-2100.	1.5	72
86	Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Annals of Oncology, 2015, 26, 2107-2113.	1.2	85
87	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Targeted Oncology, 2015, 10, 517-522.	3.6	49
88	Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Annals of Oncology, 2015, 26, 1128-1133.	1.2	81
89	Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation. Future Oncology, 2015, 11, 3083-3090.	2.4	8
90	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. Journal of Urology, 2015, 193, 41-47.	0.4	58

#	Article	IF	Citations
91	High neutrophil to lymphocyte ratio (NLR) persistence during enzalutamide to predict poor clinical outcome in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2015, 33, e16059-e16059.	1.6	2
92	Genetic interaction ofP2X7receptor andVEGFR-2polymorphisms identifies a favorable prognostic profile in prostate cancer patients. Oncotarget, 2015, 6, 28743-28754.	1.8	21
93	Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. Future Oncology, 2014, 10, 1741-1750.	2.4	12
94	Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castrationâ€resistant prostate cancer patients. Cancer, 2014, 120, 3923-3931.	4.1	33
95	Kidney Diseases Associated With Anti-Vascular Endothelial Growth Factor (VEGF). Medicine (United) Tj ETQq1 1 0.784314 rgBT /Over	1.0	138
96	Early and prolonged response to pazopanib in a patient with multiple metastases from renal cell carcinoma: a case report. Tumori, 2014, 100, e83-6.	1.1	0
97	VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. British Journal of Cancer, 2013, 109, 957-964.	6.4	41
98	METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATIONâ€RESISTANT PROSTATE CANCER. Journal of the American Geriatrics Society, 2010, 58, 986-988.	2.6	27
99	Metronomic Chemotherapy for Metastatic Prostate Cancer. Drugs and Aging, 2010, 27, 689-696.	2.7	21